Early administration of SARS-CoV-2 convalescent plasma reduces outpatient hospitalizations

The results of a nationwide, multicenter clinical trial led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health provides solid evidence for the use of plasma from convalescent patients — those who have recovered from the disease and whose blood contains antibodies against SARS-CoV-2, the virus that causes COVID-19 — as an early treatment.